Belgium· BE-AMP-SAM255254-00
Fuzeon 90 mg/ml
A enfuvirtide product containing enfuvirtide, registered in Belgium by Roche Registration. The same ATC class is registered in 10 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Enfuvirtide is registered in 10 of 19 countries.
Countries holding a registration under ATC J05AX07 (enfuvirtide), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 6 of them publish a price we can compare per daily dose
Enfuvirtide · ATC J05AX07
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Enfuvirtide
- Manufacturer
- Roche Registration
- Country
- Belgium (BE)
- ATC code
- J05AX07
- ATC class
- Enfuvirtide
- Defined daily dose
- 0.18 g, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb1790823
- be_apb0775924
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for enfuvirtide.
Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Enfuvirtide · interactions on record
2 records
- 2 moderate
Most severe, free to view
- Darunavir and cobicistatJ05AR14moderate
- CobicistatV03AX03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Enfuvirtide in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenFuzeon 90 mg/ml Pulver och vätska till injektionsvätska, lösningRoche Registration GmbH
- SpainFUZEON 90 mg/ml POLVO Y DISOLVENTE PARA SOLUCION INYECTABLERoche Registration Gmbh
- IcelandFuzeonRoche Registration GmbH*
- PolandFuzeonRoche Registration GmbH
- FinlandFuzeonRoche Registration GmbH
- FranceFUZEON 90 mg/ml, poudre et solvant pour solution injectableROCHE REGISTRATION (ALLEMAGNE)
- United KingdomFuzeon 108mg powder and solvent for solution for injection vialsRoche Products Ltd
- IrelandFuzeonRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Fuzeon
- Liechtenstein · Fuzeon
- Norway · Fuzeon
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/95961315-ee0b-446d-a785-0ba5279e331d GET /v1/drugs/95961315-ee0b-446d-a785-0ba5279e331d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solvent for solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Fuzeon 90 mg/ml",
"name_fr": "Fuzeon 90 mg/ml",
"name_nl": "Fuzeon 90 mg/ml",
"amp_code": "SAM255254-00",
"strengths": [
"90.0000"
],
"pack_count": 1,
"substances": [
"Enfuvirtide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Enfuvirtide",
"authorisation_numbers": [
"EU/1/03/252/001"
]
}See everything about enfuvirtide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.